| MEN1 mutations mediate clinical resistance to menin inhibition F Perner, EM Stein, DV Wenge, S Singh, J Kim, A Apazidis, ... Nature 615 (7954), 913-919, 2023 | 73 | 2023 |
| CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis AJ Dunbar, D Kim, M Lu, M Farina, RL Bowman, JL Yang, Y Park, ... Blood, The Journal of the American Society of Hematology 141 (20), 2508-2519, 2023 | 26 | 2023 |
| BMP2/SMAD pathway activation in JAK2/p53-mutant megakaryocyte/erythroid progenitors promotes leukemic transformation B Li, W An, H Wang, T Baslan, S Mowla, A Krishnan, W Xiao, RP Koche, ... Blood, The Journal of the American Society of Hematology 139 (25), 3630-3646, 2022 | 15 | 2022 |
| Therapeutic efficacy of combined JAK1/2, Pan-PIM, and CDK4/6 inhibition in myeloproliferative neoplasms RK Rampal, M Pinzon-Ortiz, AVH Somasundara, B Durham, R Koche, ... Clinical Cancer Research 27 (12), 3456-3468, 2021 | 14 | 2021 |
| Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms AJ Dunbar, RL Bowman, YC Park, K O'Connor, F Izzo, RM Myers, ... Cancer discovery 14 (5), 737-751, 2024 | 9 | 2024 |
| Jak2V617F reversible activation shows an essential requirement for Jak2V617F in myeloproliferative neoplasms (MPNs) A Dunbar, RL Bowman, Y Park, F Izzo, RM Myers, A Karzai, W Jun Kim, ... Blood 140 (Supplement 1), 803-804, 2022 | 7 | 2022 |
| The BMP/SMAD pathway is a key mediator of leukemic transformation of TP53-Mutant Post-MPN AML B Li, W An, H Wang, A Krishnan, S Mowla, T Baslan, R Koche, W Xiao, ... Blood 138, 626, 2021 | 2 | 2021 |
| Development of a customizable mouse backbone spectral flow cytometry panel to delineate immune cell populations in normal and tumor tissues ALF Longhini, I Fernández-Maestre, MC Kennedy, MG Wereski, S Mowla, ... Frontiers in Immunology 15, 1374943, 2024 | 1 | 2024 |
| Modeling clonal evolution and oncogenic dependency in vivo in the context of hematopoietic transformation RL Bowman, A Dunbar, T Mishra, W Xiao, MR Waarts, IF Maestre, ... bioRxiv, 2022.05. 18.492524, 2022 | 1 | 2022 |
| CRISPR Dependency Screens in Primary Hematopoietic Stem Cells Identify KDM3B as a Genotype-specific Vulnerability in IDH2- and TET2-mutant Cells MR Waarts, S Mowla, M Boileau, AR Martinez Benitez, J Sango, M Bagish, ... Cancer Discovery, OF1-OF19, 2024 | | 2024 |
| Combination JAK1/2 and CDK8/19 inhibition demonstrates enhanced efficacy in myeloproliferative neoplasms Z Zaroogian, E Adamczyk, A Moszyńska, M Obacz, U Pakulska, B Durham, ... Cancer Research 84 (6_Supplement), 7225-7225, 2024 | | 2024 |
| P986: COMBINATION JAK1/2 AND CDK8/19 INHIBITION DEMONSTRATES ENHANCED EFFICACY IN MYELOPROLIFERATIVE NEOPLASMS Z Zaroogian, E Adamczyk, A Moszyńska, M Obacz, U Pakulska, B Durham, ... HemaSphere 7 (S3), e133428d, 2023 | | 2023 |
